approval
saveRYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
community read0 votes
Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalNov 7, 2025 · 332d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalOct 8, 2025 · 362d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalSep 3, 2025 · 397d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalAug 14, 2025 · 417d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalFeb 14, 2025 · 598d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalAug 19, 2024 · 777d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalMar 1, 2024 · 948d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalNov 4, 2022 · 1431d ago
same company · ±60 days · 6
- approvalguselkumab: TREMFYA (GUSELKUMAB) — FDA approvalSep 11, 2024
- approvalerdafitinib: BALVERSA (ERDAFITINIB) — FDA approvalOct 9, 2024
- approvallazertinib mesylate: LAZCLUZE (LAZERTINIB MESYLATE) — FDA approvalAug 19, 2024
- approvalamivantamab: RYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalAug 19, 2024
- approvalapalutamide: ERLEADA (APALUTAMIDE) — FDA approvalAug 2, 2024
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJul 30, 2024
comments(0)
5-min edit window · permanent after that